Literature DB >> 2940974

Tissue penetration of ciprofloxacin after single and multiple doses.

M LeBel, F Vallée, M G Bergeron.   

Abstract

The pharmacokinetics and the suction-induced blister fluid penetration of ciprofloxacin were compared after a single dose (500 mg) and after multiple dosing (500 mg q8h for 13 doses). Significantly higher peak levels of ciprofloxacin in serum were observed after multiple dosing (3.51 versus 2.26 micrograms/ml; P less than 0.01). Increased elimination half-life occurred after multiple dosing; this seems to be mostly related to decreased systemic clearance secondary to a diminished nonrenal clearance (240.0 versus 125.0 ml/min). Ciprofloxacin appeared rapidly in the blister fluid, and the percentage of penetration (AUC0-tBF/AUC0-t serum) yielded values of 88.8 versus 84.7% after single and multiple doses, respectively. Ciprofloxacin levels in serum and blister fluid at the end of the dosing interval (8 h) were superior or almost superior to MICs for sensitive organisms including Pseudomonas aeruginosa. Comparative studies of ciprofloxacin metabolite excretion after multiple doses in healthy subjects and in renal insufficiency patients are needed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2940974      PMCID: PMC180421          DOI: 10.1128/AAC.29.3.501

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

2.  Enoxacin raises plasma theophylline concentrations.

Authors:  W J Wijnands; C L van Herwaarden; T B Vree
Journal:  Lancet       Date:  1984-07-14       Impact factor: 79.321

3.  Noncompartmental determination of the steady-state volume of distribution during multiple dosing.

Authors:  I L Smith; J J Schentag
Journal:  J Pharm Sci       Date:  1984-02       Impact factor: 3.534

4.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

5.  [Calculation of initial values of pharmacokinetic using a programmable calculator].

Authors:  P P Le Blanc; J Dumas
Journal:  Therapie       Date:  1983 Jan-Feb       Impact factor: 2.070

6.  Noncompartmental determination of the steady-state volume of distribution for any mode of administration.

Authors:  D Perrier; M Mayersohn
Journal:  J Pharm Sci       Date:  1982-03       Impact factor: 3.534

7.  Activity of ciprofloxacin (BAYo 9867) against Pseudomonas aeruginosa and ampicillin-resistant Enterobacteriaceae.

Authors:  C Roy; A Foz; C Segura; M Tirado; M Teixell; D Teruel
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

Review 8.  Biliary excretion of drugs and other xenobiotics.

Authors:  W G Levine
Journal:  Annu Rev Pharmacol Toxicol       Date:  1978       Impact factor: 13.820

9.  In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

Authors:  G M Eliopoulos; A Gardella; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

10.  Difference in blister fluid penetration after single and multiple doses of ceftriaxone.

Authors:  M LeBel; S Grégoire; M Caron; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

View more
  27 in total

Review 1.  Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.

Authors:  A Aminimanizani; P Beringer; R Jelliffe
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients.

Authors:  M LeBel; M G Bergeron; F Vallée; C Fiset; G Chassé; P Bigonesse; G Rivard
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

3.  Calculation of the antibiotic level in the lung tissue and bronchial secretion with an oral controlled-release dosage form.

Authors:  M Saïdna; E M Ouriemchi; J M Vergnaud
Journal:  Inflammopharmacology       Date:  1998       Impact factor: 4.473

Review 4.  Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response.

Authors:  D E Nix; S D Goodwin; C A Peloquin; D L Rotella; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

Review 5.  Mycobacteria and the new quinolones.

Authors:  D C Leysen; A Haemers; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

6.  Pharmacokinetics of a novel quinolone, AT-4140, in animals.

Authors:  S Nakamura; N Kurobe; T Ohue; M Hashimoto; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

7.  Pharmacokinetics of ciprofloxacin in the elderly: increased oral bioavailability and reduced renal clearance.

Authors:  B Ljungberg; I Nilsson-Ehle
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-06       Impact factor: 3.267

Review 8.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

9.  Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model.

Authors:  S L Kang; M J Rybak; B J McGrath; G W Kaatz; S M Seo
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

10.  Interactions of ciprofloxacin with clindamycin, metronidazole, cefoxitin, cefotaxime, and mezlocillin against gram-positive and gram-negative anaerobic bacteria.

Authors:  J L Whiting; N Cheng; A W Chow
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.